A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was, in patients with severe aortic stenosis, can balloon valvuloplasty be used as a bridge to aortic valve replacement? Altogether 463 papers were found using the reported search, of which 11 papers represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. We conclude that balloon aortic valvuloplasty is recommended as a bridge to aortic valve replacement (AVR) or transcatheter aortic valve implantation (TAVI) in patients with severe symptomatic aortic stenosis. Institutional practices, local and logistic factors can affect patient selection and management approaches to severe aortic stenosis, but having the facility to offer balloon aortic valvuloplasty (especially in the TAVI era) provides another management option for patients who would otherwise have been considered unacceptably high risk for aortic valve surgery. The increased incidence of balloon aortic valvuloplasty mirrors the increase in the use of TAVI with a sharp increase in activity from 2006. Success rates for bridging from balloon aortic valvuloplasty to definite surgical intervention are in the range 26.3-74%, with AVR or TAVI occurring within 8 weeks to 7 months. Complications from balloon aortic valvuloplasty such as aortic regurgitation (AR) can be managed successfully. Up to 40% of patients selected by balloon aortic valvuloplasty to have TAVI or AVR do not have these procedures within 2 years. While most of these patients are excluded for objective clinical reasons such as terminal disease/malignancy or other persistent contraindication, some patients refuse definitive treatment and others die while on the waiting list. Outcomes in patients bridged to AVR/TAVI are better than in patients treated with balloon aortic valvuloplasty only. Owing to the high mortality of patients in this cohort without destination therapy, delays to progression to TAVI or AVR should be avoided in selected patients. A discussion with the patient about expectations, mortality and morbidity risks with all management options will aid decision-making.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] . 
THREE-PART QUESTION

CLINICAL SCENARIO
A 79-year old man was referred to the clinic with symptomatic severe aortic stenosis. He had been under follow-up with the cardiologists for 10 years with asymptomatic aortic stenosis but had developed symptoms of breathlessness on maximal exertion over the past 2 months. Echocardiography showed him to have severe aortic stenosis, with an ejection fraction of 15%; other valves were normal with no coronary artery disease. He had good pulmonary reserve and no other comorbidities; he did not meet the criteria for transcatheter aortic valve replacement (AVR). This patient needed an AVR but was high risk due to poor left ventricular function. Would temporary relief of the aortic stenosis by balloon aortic valvuloplasty allow recovery of left ventricular function prior to the definitive operation? We resolved to check the literature. BAV alone (n = 387; 81.9%) BAV as a bridge (n = 85, 18.1%) to (n = 65, TAVR; n = 20, SAVR)
There was no significant difference between the two groups in mean age (81.7 ± 8.3 vs 83.2 ± 10.9 years, P = 0.18), Society of Thoracic Surgeons score (13.1 ± 6.2 and 12.4 ± 6.4, P = 0.4), log EuroSCORE (45.4 ± 22.3 vs 46.9 ± 21.8, P = 0.43)
The mean increase in aortic valve area 0.39 ± 0.25 in the BAV alone group and 0.42 ± 0.26 in the BAV as a bridge group, P = 0.33
The decrease in mean gradient was 24. 
Continued
We excluded papers relating to valvuloplasty in the paediatric population, focusing on valvuloplasty for degenerative aortic valve disease. Papers that provided the best evidence to answer the question are presented in Table 1 .
RESULTS
Balloon aortic valvuloplasty has a role in the management of congenital aortic stenosis but its role in degenerative disease is still limited and so is not considered a substitute for AVR. The 2014 AHA/ACC guidelines recommend balloon aortic valvuloplasty as a reasonable bridge to AVR or transcatheter aortic valve implantation (TAVI) in patients with severe symptomatic aortic stenosis (Class IIb, Level of Evidence C) [2] .
Institutional practices and personal biases can affect patient selection and management approaches to severe aortic stenosis [3] but having the facility to offer balloon aortic valvuloplasty (especially in the TAVI era) provides another management option for patients who would otherwise have been considered unacceptably high risk for aortic valve surgery.
Indications for balloon aortic valvuloplasty as a bridge to AVR or TAVI included haemodynamically unstable patients at high risk for AVR or TAVI, poor left ventricle function, cardiogenic shock, severe mitral regurgitation and malignancy. Balloon aortic valvuloplasty was also used to distinguish between breathless due to aortic stenosis or respiratory pathology, with patients showing improvement going on to have aortic valve surgery [3] .
Malkin et al. [4] demonstrated the use of balloon aortic valvuloplasty to triage patients with destination valve therapy offered based on the patients' clinical response. Malkin et al. [4] also suggested the use of balloon aortic valvuloplasty to screen for the possibility of coronary ostial occlusion by native leaflets prior to TAVI.
Balloon aortic valvuloplasty intuitively resulted in improvements in objective measures such as the gradient across the aortic valve post dilatation, left ventricular systolic pressure and varying improvements in aortic valve area (AVA); there were also improvements in subjective measures such as NYHA class [5] . Most studies identified consisted of consecutive patient series with no control group and so, as a result, the benefit or risk of balloon aortic valvuloplasty could not be determined in relation to the natural history of degenerative aortic stenosis.
The reported mortality after balloon aortic valvuloplasty was up to 17% [3] with the causes of death including sudden death, cardiogenic shock [sometimes due to aortic regurgitation (AR)] and embolic phenomenon. Success rates (patients surviving balloon aortic valvuloplasty to undergo AVR or TAVI) for bridging from balloon aortic valvuloplasty to definite surgical intervention were in the range 26.3-74% (AVR or TAVI within median times of 8 weeks to 7 months). Saia et al. described a technique to manage acute AR during the balloon aortic valvuloplasty procedure [6] . In their series of 415 patients undergoing balloon aortic valvuloplasty [7] , 11 patients (2.3%) had severe AR during the procedure with 8 successfully managed in the catheter laboratory. Three patients left the catheter laboratory with severe AR: 1 died of cardiogenic shock in hospital, 1 died 2 months later of terminal heart failure and 1 underwent successful AVR 9 months after balloon aortic valvuloplasty.
The later study periods (after 2006) included more patients being bridged to TAVI than to AVR, reflecting the change in practice with the wider availability and use of TAVI. The duration from balloon aortic valvuloplasty to TAVI or AVR varied widely, probably reflecting local practices and workloads. Balloon aortic valvuloplasty in a lot of cases was used as an aid to diagnosis to determine the suitability of these patients for definitive surgical therapy (AVR or TAVI depending on local criteria). It would be reasonable to suggest that once patients have been deemed suitable for AVR or TAVI, this should take place as soon as possible. Saia et al. report that, in their series, up to 40% of patients selected to have TAVI or AVR by balloon aortic valvuloplasty did not have these procedures within 2 years [7] . They report that while most of these patients were excluded for objective clinical reasons such as terminal disease/malignancy or other persistent contraindication, some patients refused definitive treatment and others died on the waiting list. Outcomes in patients bridged to AVR/TAVI were better than in patients treated with balloon aortic valvuloplasty only [7] [8] [9] . Khawaja et al. also state that the high mortality among this patient cohort without destination therapy could explain the discrepancy observed between the number of patients who undergo balloon aortic valvuloplasty and patients who receive AVR or TAVI [8] . Where possible, excessive delay between balloon aortic valvuloplasty and destination therapy should be avoided in selected patients.
CLINICAL BOTTOM LINE
Balloon aortic valvuloplasty (balloon aortic valvuloplasty) is recommended as a bridge to AVR or TAVI in patients with severe symptomatic aortic stenosis. It is, however, a risky manoeuvre and cardiac surgeons consider this option only in very selected patients, who have been considered unacceptably high risk for AVR or TAVI. Success rates for bridging from balloon aortic valvuloplasty to definite surgical intervention are in the range 26.3-74%, with AVR or TAVI occurring within median times of 8 weeks to 7 months. Due to the high mortality of patients in this cohort without destination therapy, delays to destination therapy should be avoided. A discussion with the patient about expectations, mortality and morbidity risks with all management options will aid decision-making.
